The obesity duopoly has been pierced as Amgen positions itself to have a drug on the market in a few years. While this adds ...
The market didn't appreciate Amgen 's ( AMGN 1.00%) latest clinical data update, with the biopharma's shares falling more ...
We came across a bullish thesis on Amgen Inc. (AMGN) on Disruptive analytics’ Substack by Magnus Ofstad. In this article, we ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback